Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia
- Schizophrenia
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- TG Therapeutics, Inc.
- Enrolment target
- 60
- Started
- 27 July 2026
- Main results due
- 12 December 2028
- Study sites
- 2
- Registry updated
- 23 September 2026
Can you take part?
- Ages 18 years to 60 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: 1. Primary diagnosis of schizophrenia. 2. Treatment-resistant. 3. Requires antipsychotic treatment and is currently receiving "standard of care". 4. PANSS total score between 80 and 120, inclusive at screening and baseline. Exclusion Criteria 1. Any primary Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) disorder other than schizophrenia. 2. Ongoing clozapine treatment. 3. Risk for suicidal behavior. 4. Any severe or uncontrolled medical condition that could affect the participant's ability to participate. Note: Other protocol-specified Inclusion/Exclusion criteria may apply
What this study is about
In the sponsor’s own words, from the registry.
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.
Study sites(2)
TG Therapeutics Investigational Trial Site
Little Rock, Arkansas, United States
Recruiting
TG Therapeutics Investigational Trial Site
Richardson, Texas, United States
Recruiting
Showing 2 of 2 sites. 2 of the 2 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07680946. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me